MedPath

Bioavailability Study of DP-R202 in Healthy Male Volunteers Under Fed Conditions

Phase 1
Completed
Conditions
Healthy
Interventions
Dietary Supplement: High fat meal
Registration Number
NCT01421576
Lead Sponsor
Alvogen Korea
Brief Summary

A randomized, open-label, single-dose, crossover clinical trial to evaluate the food effect on the pharmacokinetics of DP-R202 tablet after oral administration in healthy male volunteers.

Detailed Description

The number of patient is twenty-four.Patients were randomly assigned either DP-R202(Sarpogrelate HCL 300mg, qd) under fasting condition or DP-R202(Sarpogrelate HCL 300mg, qd) after eating foods.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
24
Inclusion Criteria
  • 20 to 55 years of healthy volunteers
Exclusion Criteria
  • Hypersensitivity Reaction about Sarpogrelate HCL or other antiplatelets

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
DP-R202High fat mealunder fed condition
High fat mealHigh fat meal-
Primary Outcome Measures
NameTimeMethod
Composite of Pharmacokinetics(Cmax, AUClast)24h
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Samsung Medical Center

🇰🇷

Seoul, Gangnam, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath